STOCK TITAN

Lucid Diagnostics Inc. - LUCD STOCK NEWS

Welcome to our dedicated page for Lucid Diagnostics news (Ticker: LUCD), a resource for investors and traders seeking the latest updates and insights on Lucid Diagnostics stock.

Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage medical diagnostics company dedicated to cancer prevention, particularly focusing on patients with gastroesophageal reflux disease (GERD). GERD, commonly known as chronic heartburn or acid reflux, places millions at risk of developing esophageal precancer and the highly lethal esophageal adenocarcinoma. Lucid's groundbreaking products, EsoCheck and EsoGuard, are at the forefront of early detection and prevention.

EsoGuard is a bisulfite-converted Next Generation Sequencing (NGS) DNA assay performed on surface esophageal cells collected with the EsoCheck device. This test quantifies methylation at 31 sites on two genes, Vimentin (VIM) and Cyclin A1 (CCNA1), detecting esophageal precancer and cancer with over 90% sensitivity and specificity. EsoCheck is an FDA 510(k) and CE Mark cleared noninvasive swallowable balloon capsule catheter device. This device can sample surface esophageal cells in less than five minutes, providing an effective, non-invasive alternative to costly and invasive endoscopy.

Lucid has shown substantial progress, including solid revenue growth on stable test volumes. Their revenue cycle management processes are improving, and the CYFT program targeting specific groups like firefighters is thriving. Their direct contracting initiative is also accelerating, with near-term prospects for delivering contracts, testing, and revenue.

Recently, Lucid announced a partnership with the Esophageal Cancer Action Network (ECAN) to highlight Esophageal Cancer Awareness Month. Public service videos run on Nasdaq's billboard in Times Square, spreading awareness about the link between heartburn and esophageal cancer.

Lucid's peer-reviewed publication of positive data from a National Cancer Institute (NCI)-sponsored study confirmed the high sensitivity and specificity of the EsoGuard test. This significant milestone supports their goal of widespread screening and early detection, moving towards Medicare coverage.

Lucid continues to advance its operations and strategies, recently closing a $30 million preferred stock financing to support their growth. They are on track to achieve key milestones, including expanded private and public coverage and direct contracting. Lucid's clinical evidence base for EsoGuard is robust, further enhancing their line of sight to Medicare coverage.

For more information, visit www.luciddx.com and their parent company PAVmed at www.pavmed.com.

Rhea-AI Summary

Lucid Diagnostics Inc. (NASDAQ: LUCD), a cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (NASDAQ: PAVM, PAVMZ), announced its participation in the 22nd Annual Needham Healthcare Conference. Executives Dr. Lishan Aklog and Dennis McGrath will present on April 20, 2023, at 11:00 AM ET. Lucid focuses on patients with gastroesophageal reflux disease (GERD), a condition that increases the risk of esophageal precancer and cancer. Their flagship product, the EsoGuard® Esophageal DNA Test, is a non-invasive tool designed for early cancer detection in at-risk patients. For those interested in meeting with management during the conference, inquiries can be directed to Needham representatives. For more details, visit luciddx.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.09%
Tags
conferences
-
Rhea-AI Summary

Lucid Diagnostics Inc. (Nasdaq: LUCD), a cancer prevention diagnostics company and a subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), announced that its leadership team, including Dr. Lishan Aklog and Dennis McGrath, will present at the 22nd Annual Needham Healthcare Conference on April 20, 2023, at 11:00 AM ET.

Lucid's focus is on patients with gastroesophageal reflux disease (GERD), at risk of esophageal cancer. Their EsoGuard® Esophageal DNA Test, a non-invasive diagnostic tool, is designed for early detection of esophageal precancer. This test is significant as it is the first commercially available screening tool targeting at-risk GERD patients.

For more details, visit luciddx.com or pavmed.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.09%
Tags
conferences
-
Rhea-AI Summary

Lucid Diagnostics Inc. announced the publication of a Future Effective Local Coverage Determination (LCD) by the MolDX Program, effective May 14, 2023. This foundational LCD establishes coverage criteria for molecular testing of esophageal precancer and cancer for Medicare beneficiaries. Lucid plans to submit its EsoGuard Esophageal DNA Test for Technical Assessment under this LCD by the end of 2023, aiming to provide non-invasive testing alternatives to traditional endoscopy. The LCD incorporates feedback from stakeholders and aligns with the American College of Gastroenterology's guidelines, emphasizing early detection to prevent esophageal cancer deaths.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
none
Rhea-AI Summary

PAVmed Inc. (NASDAQ: PAVM, PAVMZ) announced a business update and financial results for the year ended December 31, 2022. The company's restructuring plan has extended its cash runway, securing $24.6 million financing for Lucid Diagnostics, which is expected to last into 2024. Veris Health launched its Cancer Care Platform, enhancing patient monitoring. EsoGuard testing volume is growing, with recent agreements increasing access to up to 60 million consumers through MultiPlan. However, 2022 revenues were just $0.4 million, with a net loss of $89.2 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.91%
Tags
-
Rhea-AI Summary

Lucid Diagnostics (NASDAQ: LUCD) reported significant growth in EsoGuard® test volumes, with 4Q22 showing an 8% sequential increase and a remarkable 288% year-over-year rise. The company anticipates 1Q23 to reflect approximately 1,600 tests, marking a 36% sequential and 300% annual growth. A strategic in-network agreement with MultiPlan broadens access to EsoGuard for 60 million consumers. Additionally, Lucid secured $24.6 million in financing through preferred stock and debt offerings, enhancing its cash runway into 2024 while focusing on commercial execution. Despite these positives, revenues remain low, with 4Q22 revenues at $0.1 million, and a net loss of $14.9 million reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.83%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.83%
Tags
none
Rhea-AI Summary

PAVmed Inc. (NASDAQ: PAVM, PAVMZ) announces a business update conference call scheduled for March 15, 2023, at 8:30 AM EST. CEO Lishan Aklog and CFO Dennis McGrath will discuss the company's growth strategy and report on the fourth-quarter 2022 financial results. Investors can access the webcast on the company's investor relations website or join via telephone with specific dial-in information provided. PAVmed operates in medical technology, with its subsidiaries, Lucid Diagnostics (NASDAQ: LUCD) and Veris Health, focusing on innovative cancer diagnostics and personalized cancer care, respectively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
none
-
Rhea-AI Summary

Lucid Diagnostics Inc. (NASDAQ: LUCD), a cancer prevention medical diagnostics company, will host a business update conference call on March 14, 2023, at 8:30 AM EST. The call will include insights from CEO Lishan Aklog, M.D., about the company's operations and growth strategy, alongside a discussion on fourth-quarter 2022 financial results by CFO Dennis McGrath. Investors can access the call via telephone or through a webcast available on the company's website. Lucid focuses on patients with gastroesophageal reflux disease (GERD), offering the EsoGuard® Esophageal DNA Test and EsoCheck® collection device as tools for early detection of esophageal cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
none
-
Rhea-AI Summary

PAVmed Inc. has launched its Veris Cancer Care Platform (Veris CCP) following the onboarding of its first cohort of cancer patients. This platform enhances personalized cancer care through remote patient monitoring (RPM) using VerisBox™ devices and a patient smartphone app. The platform allows patients to transmit real-time physiological data and report symptoms to their healthcare team via a cloud-based clinician portal, which also enables billing for RPM services. CEO Lishan Aklog expressed optimism about delivering recurring revenue through the software-as-a-service model. Veris Health, PAVmed's subsidiary, aims to expand its offerings and improve patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
none
Rhea-AI Summary

On February 15, 2023, Lucid Diagnostics (NASDAQ: LUCD) announced the successful completion of its first #CheckYourFoodTube Precancer Testing Event in collaboration with the San Antonio Fire Department. The event aimed at detecting esophageal precancer in nearly 400 at-risk firefighters, with 391 participating. The EsoGuard Esophageal DNA Test was employed, showing potential to detect precancerous changes early. Lucid aims to expand its satellite testing centers in support of National Cancer Prevention Month, emphasizing the importance of early detection in preventing esophageal cancer, particularly among those with increased risks, such as firefighters.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.97%
Tags
none

FAQ

What is the current stock price of Lucid Diagnostics (LUCD)?

The current stock price of Lucid Diagnostics (LUCD) is $0.781 as of December 20, 2024.

What is the market cap of Lucid Diagnostics (LUCD)?

The market cap of Lucid Diagnostics (LUCD) is approximately 46.9M.

What is Lucid Diagnostics Inc.?

Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage medical diagnostics company focused on cancer prevention, particularly for patients with gastroesophageal reflux disease (GERD).

What are EsoCheck and EsoGuard?

EsoCheck is a noninvasive device for collecting esophageal cells, and EsoGuard is a DNA assay test performed on these cells to detect esophageal precancer and cancer.

Why are GERD patients at risk?

GERD can lead to esophageal precancer and cancer, specifically esophageal adenocarcinoma, which is highly lethal if not detected early.

How does EsoGuard work?

EsoGuard quantifies DNA methylation at specific sites to detect esophageal precancer and cancer with high sensitivity and specificity.

What recent achievements has Lucid Diagnostics announced?

Lucid announced partnerships, positive clinical study results, and financial growth, including a $30 million preferred stock financing.

What partnerships has Lucid Diagnostics formed?

Lucid partnered with the Esophageal Cancer Action Network (ECAN) to increase awareness about the links between heartburn and esophageal cancer.

What are the financial highlights for Lucid Diagnostics?

Lucid has shown solid revenue growth, improved revenue cycle management, and successful execution of their commercial strategy.

What is the significance of the NCI-sponsored study?

The study validated EsoGuard's high sensitivity and specificity, marking a significant step towards widespread screening and Medicare coverage.

How does Lucid's technology compare to traditional methods?

Lucid's technology offers a non-invasive alternative to endoscopy, making it more accessible and cost-effective for early detection of esophageal precancer.

What are Lucid's future plans?

Lucid aims to expand private and public coverage, secure Medicare coverage for EsoGuard, and continue their commercial growth and partnerships.

Lucid Diagnostics Inc.

Nasdaq:LUCD

LUCD Rankings

LUCD Stock Data

46.87M
23.24M
59.09%
4.18%
0.53%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
NEW YORK